AHDMP perspective on first wave of the COVID-19 pandemic

Fionnuala King, Chief Pharmacist, HSE Acute Hospitals Drug Management Programme

Health Service Executive

SENIOR LEADERSHIP TEAM





National Drug Management Programme

AHDMP Governance Structure



COVID-19

Three areas of AHDMP practice:

- COVID-19 Medicines Criticality Assessment Group
- Development of evidence based guidance on the use of drug treatments in the management of COVID-19.
- Clinical trials

Engagement with other HSE Pharmacists to share information & prevent duplication of queries.

Clinical trials

- AHDMP:
  - “COVID-19 is a novel infection and treatment should be initiated in the context of an ethically approved clinical trial wherever possible.”
- March 2020 CHMP
  - “A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19”
- WHO Solidarity Trial. DOH sponsored adaptive collaborative study.

Medicines Criticality Assessment Group

- Objective: “COVID-19 related medicines supply issues and shortages”
- Multi-agency group convened and chaired by DOH, sub-group of NPHET.
- Core membership included: HPRA – Scientific Affairs & Medicines Shortages Framework reps , PCRS, NCCP, AHDMP, National Clinical Programme Infectious Diseases
- Expert input AMRIC, National Clinical Programme leads, Prison Service Pharmacy lead, Medication Safety & National Isolation Unit
- Periodic update from the NPHET Modelling group.

AHDMP role

- Engagement with National Clinical Programmes to identify critical (“mission critical”) medicines
- Structured engagement with MAHs known to supply to Irish hospitals
- Cross-sectoral knowledge and experience
- Demand modelling supported by data from acute hospital pharmacists, NOCA & HPSC
- Follow up and liaison with MAHs.
- Data provided weekly from MAHs, EMP suppliers & wholesalers

Supply chain evaluation

- Identify additionality in supply chains for COVID-19 use of medications
  - Not all patients will have access to a clinical trial
  - Risk of inequity of access
- Weekly tracking of stock levels of “critical products” from March to June 2020 including targeted direct procurement
- Data management support & tracking of MAH responses from the National Pharmacy Procurement Support Team
- Evaluation of supply signals from other EU countries

Supply chain risk mitigation

- With PCRS, design processes to protect supply for existing patients on products for licensed indications e.g. all de novo Rx hydroxychloroquine referred to PCRS for approval, parallel supply chain agreed with MAH for hospital COVID-19 supplies.
- Direct engagement HPRA to facilitate addition stock via BSRs
- Communication with National Clinical programmes to alter prescribing practices to prevent outages of single lines
- Risk escalation & mitigation to NPHET
- Direct procurement working with known suppliers

Communication, communication, communication

- Hospital Pharmacists
- Community Pharmacist (chloroquine access)
- Direct media queries
- Support media appearances by HSE staff
- National Clinical Programmes
- FOI requests
- DOH Stakeholder briefings
- NPHET briefings
- CHO pharmacists
- Private hospital pharmacists

AHDMP COVID-19 Clinical Advisory Group

Purpose: "Clinical Advisory Group for medicines used in the management of patients with COVID-19"

- Chair Clinical Lead for Infectious Diseases
- National Clinical Programme for Critical Care
- National Clinical Programme for Respiratory Medicine
- Irish Haematology Society
- AHDMP Pharmacists
- COVID 19 Evidence Review Group Lead

Chair

NCAGL AO under the governance of the Office of the Chief Clinical Officer

National guidance

Treatment in the context of a clinical trial and if not available against National Clinical Guidelines.

Process:

- Written question submitted to COVID-19 Evidence Review Group
- Experts in evidence synthesis from the Response informs (interim) guidance from NCPE, MMP and NMIC
- Review by relevant National Clinical Programme Nominees
- Approval by NCAGL AO
- Iterative approach, review, revise as evidence emerges

COVID-19

- Guidance Documents COVID-19
- Advisory Statements COVID-19
- Rapid Evidence Reviews COVID-19

In this section

- National Drugs Management Scheme
- Communications
- Clinical Protocols
- Guidelines
- COVID-19

Autumn 2020

- Clearer knowledge of “critical drugs”.
- National Office of Clinical Audit (NOCA) ICU audit- provision of information on “demand”
- Targeted engagement with MAH on a limited number of medical products – “supply” information
- On-going modelling of drug demand
- EU Commission Joint Procurement Framework participant assuring access to remdesivir

Gaps…

- Still no knowledge of stock within hospitals.
- Agile communication pathways
- Real world patient management insights


Any
Questions